Abbott Laboratories (ABT) — Analyst outlook / Analyst consensus target is. Based on 40 analyst ratings, the consensus is bullish — 30 Buy, 10 Hold.
The consensus price target is $137.67 (low: $120.00, high: $158.00), representing an upside of 36.2% from the current price $101.07.
Analysts estimate Earnings Per Share (EPS) of $4.67 and revenue of $42.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $7.74 vs est $4.67 (beat +65.6%). 2025: actual $3.74 vs est $5.15 (missed -27.4%). Analyst accuracy: 61%.
ABT Stock — 12-Month Price Forecast
$137.67
▲ +36.21% Upside
Average Price Target
Based on 40 Wall Street analysts offering 12-month price targets for Abbott Laboratories, the average price target is $137.67, with a high forecast of $158.00, and a low forecast of $120.00.
The average price target represents a +36.21% change from the last price of $101.07.
Highest Price Target
$158.00
Average Price Target
$137.67
Lowest Price Target
$120.00
ABT Analyst Ratings
Buy
Based on 40 analysts giving stock ratings to Abbott Laboratories in the past 3 months
EPS Estimates — ABT
61%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $7.74
vs Est $4.67
▲ 39.6% off
2025
Actual $3.74
vs Est $5.15
▼ 37.8% off
Profitability Outlook
Strong profitability with high earnings per share. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — ABT
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $41.950B
vs Est $42.000B
▼ 0.1% off
2025
Actual $44.328B
vs Est $44.672B
▼ 0.8% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
